NDA 021850 · Santarus
Zegerid
Magnesium Hydroxide, Omeprazole, Sodium Bicarbonate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 3, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Mar 24, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
538
112 Phase 3, 27 recruiting
FAERS reports
2,739
1,742 serious, 167 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 24, 2006 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LetterReviewOther Important Information from FDA
2 products under this application
- ZEGERID · MAGNESIUM HYDROXIDE 700MG; OMEPRAZOLE 20MG; SODIUM BICARBONATE 600MG · TABLET, CHEWABLE, ORAL · Discontinued
- ZEGERID · MAGNESIUM HYDROXIDE 700MG; OMEPRAZOLE 40MG; SODIUM BICARBONATE 600MG · TABLET, CHEWABLE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydroxide" as an intervention, any sponsor and status, largest first.
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT04992208 · 31,041 participants · Start Jul 24, 2021 · Primary completion Mar 24, 2023
Drug: Experimental Group · For: COVID-19
Sites: Dali, China
- A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19Pivotal-lookingStatus unknown
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT04646590 · 28,904 participants · Start Dec 16, 2020 · Primary completion Nov 28, 2021
Drug: Recombinant new coronavirus vaccine (CHO cell) group; Recombinant new coronavirus vaccine (CHO cells) placebo group · For: Prevention of COVID-19; Safety and Efficacy
Sites: Changsha, China; Guayaquil, Ecuador; Quito, Ecuador · 18 sites in all
- The Phase Ⅱ/Ⅲ Trial of LYB001Pivotal-lookingStatus unknown
Yantai Patronus Biotech Co., Ltd.Industry
NCT05602558 · 18,000 participants (planned) · Start Dec 2022 · Primary completion Dec 2023
Drug: LYB001; Placebo · For: COVID-19
International Vaccine InstituteAcademic, hospital or other
NCT03747770 · 18,000 participants (planned) · Start Dec 17, 2018 · Primary completion Dec 2022
Drug: Bivalent HPV vaccine CERVARIX® · For: Healthy
Sites: Bangkok, Thailand
- HIV Vaccine Trial in Thai AdultsPivotal-lookingCompleted
U.S. Army Medical Research and Development CommandFederal agency
NCT00223080 · 16,402 participants · Start Oct 2003 · Primary completion Jul 2006
Drug: ALVAC-HIV vCP1521 + AIDSVAX · For: HIV Infection
Sites: Ban Lamung District, Thailand; Phan Tong District, Thailand; Sattahip District, Thailand · 8 sites in all
- Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In PeruPivotal-lookingCompleted
Universidad Peruana Cayetano HerediaAcademic, hospital or other
NCT04612972 · 12,000 participants · Start Sep 9, 2020 · Primary completion Feb 19, 2021
Drug: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo · For: COVID-19
Sites: San Martín de Porres, Peru
- Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and AdolescentsPivotal-lookingCompleted
Sinovac Research and Development Co., Ltd.Industry
NCT04992260 · 11,349 participants · Start Sep 10, 2021 · Primary completion May 31, 2023
Drug: Inactivated COVID-19 Vaccine; Controlled vaccine · For: COVID-19
Sites: Port Montt, Chile; Valdivia, Chile; Antofagasta, Chile · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease788
- acute kidney injury456
- renal failure431
- end stage renal disease212
- drug ineffective200
- renal injury195
- nausea167
- gastrooesophageal reflux disease156
- pain135
- headache131
- fatigue126
- diarrhoea109
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 26 |
| 2008 | 62 |
| 2009 | 86 |
| 2010 | 119 |
| 2011 | 145 |
| 2012 | 142 |
| 2013 | 102 |
| 2014 | 97 |
| 2015 | 148 |
| 2016 | 150 |
| 2017 | 172 |
| 2018 | 301 |
| 2019 | 513 |
| 2020 | 187 |
| 2021 | 153 |
| 2022 | 101 |
| 2023 | 45 |
| 2024 | 72 |
| 2025 | 58 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zegerid (Omeprazole/Sodium Bicarbonate)
2024 spending
$3.3M
Beneficiaries
252
667 claims
Per beneficiary
$12,949
$105.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,698,746 |
| 2021 | $7,954,260 |
| 2022 | $8,461,055 |
| 2023 | $8,514,993 |
| 2024 | $3,263,247 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Calcium hydroxide as an intracanal medication for postoperative pain during primary root canal therapy: A systematic review and meta-analysis with trial sequential analysis of randomised controlled trials.
Ahmad MZ, Sadaf D, Merdad KA, et al. · J Evid Based Dent Pract 2022 · Meta-Analysis, Systematic Review
- Outcome of pulpotomy in permanent teeth with irreversible pulpitis: a systematic review and meta-analysis.
Ather A, Patel B, Gelfond JAL, et al. · Sci Rep 2022 · Meta-Analysis, Systematic Review
- A Systematic Review and Meta-Analysis of Nonvital Pulp Therapy for Primary Teeth.
Coll JA, Vargas K, Marghalani AA, et al. · Pediatr Dent 2020 · Meta-Analysis, Systematic Review
- Primary Tooth Vital Pulp Therapy: A Systematic Review and Meta-analysis.
Coll JA, Seale NS, Vargas K, et al. · Pediatr Dent 2017 · Meta-Analysis, Systematic Review
- Success rate of permanent teeth pulpotomy using bioactive materials: A systematic review and meta-analysis of randomized clinical trials.
Silva EJNL, Pinto KP, Belladonna FG, et al. · Int Endod J 2023 · Meta-Analysis, Systematic Review
- Pulp treatment for extensive decay in primary teeth.
Smaïl-Faugeron V, Glenny AM, Courson F, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Santarus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.